1msx
From Proteopedia
(Difference between revisions)
| (7 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
{{Theoretical_model}} | {{Theoretical_model}} | ||
| - | {{Seed}} | ||
| - | [[Image:1msx.png|left|200px]] | ||
| - | + | ==HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N-AMINO-15N-IMINO- 13C-METHYL)PHENOXY]-6-[3-(15N-AMINO-13C-METHYL)PHENOXY]-3, 5-DIFLUORO-4-METHYLPYRIDINE (ZK-806299), BINDING MODEL FROM DOUBLE REDOR NMR AND MD SIMULATIONS.== | |
| - | + | <StructureSection load='1msx' size='340' side='right'caption='[[1msx]]' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1MSX FirstGlance]. <br> | |
| - | + | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1msx FirstGlance], [https://www.ebi.ac.uk/pdbsum/1msx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1msx ProSAT]</span></td></tr> | |
| - | + | </table> | |
| - | + | __TOC__ | |
| - | + | </StructureSection> | |
| - | + | [[Category: Theoretical Model]] | |
| - | + | [[Category: Large Structures]] | |
| - | + | ||
| - | == | + | |
| - | + | ||
[[Category: Dallas, J L]] | [[Category: Dallas, J L]] | ||
[[Category: Guilford, W J]] | [[Category: Guilford, W J]] | ||
| Line 25: | Line 20: | ||
[[Category: Schaefer, J]] | [[Category: Schaefer, J]] | ||
[[Category: Studelska, D R]] | [[Category: Studelska, D R]] | ||
| - | |||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Apr 8 08:01:13 2010'' | ||
Current revision
| Theoretical Model: The protein structure described on this page was determined theoretically, and hence should be interpreted with caution. |
HUMAN FACTOR XA COMPLEXED WITH 2-[3-(15N-AMINO-15N-IMINO- 13C-METHYL)PHENOXY]-6-[3-(15N-AMINO-13C-METHYL)PHENOXY]-3, 5-DIFLUORO-4-METHYLPYRIDINE (ZK-806299), BINDING MODEL FROM DOUBLE REDOR NMR AND MD SIMULATIONS.
| |||||||||||
